CTLA4IgG treatment induces long-term acceptance of rat small bowel allografts

Transplantation

Volumn 67, Issue 4, 1999, Pages 520-525

  Tarumi, Ken ^a,b   Murakami, Masaaki ^a   Yagihashi, Atsuhito ^b   Nakagawa, Izumi ^a   Hirata, Koichi ^b   Uede, Toshimitsu ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 2; INTERLEUKIN 4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DRUG TOLERANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOLOGICAL TOLERANCE; INTESTINE GRAFT; INTESTINE TRANSPLANTATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SMALL INTESTINE; STATISTICAL ANALYSIS; SURVIVAL RATE;

EID: 0033608453     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199902270-00005     Document Type: Article

References (31)

1. Jenkins MK, Schwartz RH. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J Exp Med 1987; 165: 302.
2. Mueller DL, Jenkins MK, Schwartz RH. Clonal expansion versus functional clonal inactivation: a costimulatory signaling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol 1989; 7: 445.
3. Schwartz RH. A cell culture model for T lymphocyte clonal anergy. Science 1990; 248: 1349.
4. Bierer BE, Peterson A, Gorga JC, Herrmann SH, Burakoff SJ. Synergistic T cell activation via the physiological ligands for CD2 and the T cell receptor. J Exp Med 1988; 168: 1145.
5. Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 1992; 356: 607.
6. Linsley PS, Brady W, Grosmaire L, Aruffo A, Damle NK, Ledbetter LA. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med 1991; 173: 721.
7. Van Seventer GA, Shimizu Y, Horgan KJ, Shaw S. The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells. J Immunol 1990; 144: 4579.
8. Lenschow DJ, Zeng Y, Thistlethwaite JR, et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA-4Ig. Science 1992; 257: 789.
9. Lin H, Boiling SF, Linsley PS, et al. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA-4Ig plus donor-specific transfusion. J Exp Med 1993; 178: 1801.
10. Lane P, Gerhard W, Hubele S, Lanzavecchia A, McConnell F. Expression and functional properties of mouse B7/BB1 using a fusion protein between mouse CTLA-4 and human γ1. Immunol 1993; 80: 56.
11. Thompson AW, Starzl TE. New immunosuppressive drugs: mechanistic insights and potential therapeutic advances. Immunol Rev 1993; 136: 71.
12. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991; 174: 561.
13. Larsen CP, Ritchie SC, Pearson TC, Linsley PS, Lowly RP. Functional expression of the costimulatory molecule, B7/BB1, on murine dendritic cell populations. J Exp Med 1992; 176: 1215.
14. Person TC, Alexander DZ, Winn KJ, Linsley PS, Lowly RP, Larsen CP. Transplantation tolerance induced by CTLA-4Ig. Transplantation 1994; 57: 1701.
15. Tan P, Anasetti C, Hansen JA, et al. Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J Exp Med 1993; 177: 165.
16. Turka LA, Linsley PS, Lin H, Brady W, et al. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci USA 1992; 89: 11102.
17. Nakagawa I, Murakami M, Ijima K, et al. Persistent and secondary adenovirus-mediated hepatic gene expression using adenovirus vector containing CTLA4IgG. Hum Gene Ther 1998; 9: 1739.
18. Monchik GJ, Russel PS. Transplantation of small bowel in the rat: Technical and immunological consideration. Surgery 1971; 70: 693.
19. Langrehr JM, Hoffman RA, Demetris AJ, et al. Evidence that indefinite survival of small bowel allografts achieved by a brief course of cyclosporin or FK506 is not due to systemic hyporesponsiveness. Transplantation 1992; 54: 505.
20. Yin DP, Sankary HN, Williams J, Krieger N, Fathman CG. Induction of tolerance to small bowel allografts in high-responder rats by combining anti-CD4 with CTLA4IgG. Transplantation 1996; 62: 1537.
21. Yamada A, Murakami M, Ijima K, et al. Long-term acceptance of major histocompatibility complex-mismatched cardiac allograft induced by a low dose of CTLA4IgM plus FK506. Microbiol Immunol 1996; 40: 513.
22. Dallman MJ, Larsen CP, Morris PJ. Cytokine gene transcription in vascularised organ graft: Analysis using semiquantitative polymerase chain reaction. J Exp Med 1991; 174: 493.
23. Takeuchi T, Lowly RP, Konieczny B. Heart allografts in murine systems. The differential activation of Th2 like effector cells in peripheral tolerance. Transplantation 1992; 53: 1280.
24. Dallman MJ, Roake J, Hughes D, Toogood G, Morris P. Sequential analysis of IL-2 gene transplantation in renal transplants. Transplantation 1992; 53: 683.
25. Sayegh MH, Akalin E, Hancock WW, et al. CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2. J Exp Med 1995; 181: 1869.
26. Lakkis FG, Konieczny BT, Saleem S, et al. Blocking the CD28-B7 T cell costimulation pathway induces long-term cardiac allograft acceptance in the absence of interleukin-4. J Immunol 1997; 158: 2443.
27. Takeuchi T, Ueki T, Sunaga S, et al. Murine interleukin 4 transgenic heart allograft survival prolonged with down-regulation of the Th1 cytokine mRNA in grafts. Transplantation 1997; 15: 152.
28. Judge TA, Tang A, Spain LM, Gratiot-Deans J, Sayegh MH, Turka LA. The in vivo mechanism of action of CTLA4Ig. J Immunol 1996; 156: 2294.
29. Konieczny BT, Dai Z, Elwood ET, et al. IFN-γ is critical for long-term allograft survival induced by blocking the CD28 and CD40 ligand T cell costimulation pathways. J Immunol 1998; 160: 2059.
30. Longrehr JM, Banner B, Lee K, Schraut WH. Clinical course, morphology, and treatment of chronically rejecting small bowel allografts. Transplantation 1993; 55: 242.
31. Su GL, Walgenbach KJ, Heeckt PH, et al. Increased expression of interferon-gamma in a rat model of chronic intestinal allograft rejection. Transplantation 1996; 62: 242.